Deaths due to
Officials reported 837 flu and pneumonia deaths to the CDC through its 122 Cities Mortality Reporting System during the 51st week of the year. Those deaths accounted for 6.8% of the 12,358 total deaths that week, just meeting the epidemic threshold.
The fewest deaths – 42 – were in the area that includes Minnesota, Iowa, Missouri, Kansas and Nebraska.
Influenza activity was considered “widespread” in 36 states during week 51, according to the CDC’s most recent FluView report. These states included Arkansas, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Pennsylvania, South Carolina, South Dakota, Tennessee, Texas, Virginia, Washington, Wisconsin and Wyoming.
At least 2,643 people have been hospitalized with laboratory-confirmed cases of the flu since Oct. 1, the CDC reported. That works out to a hospitalization rate of 9.7 hospitalizations per 100,000 Americans.
But the risk wasn't the same for all age groups. Senior citizens had the highest hospitalization rate, at 38.3 per 100,000 people. They were followed by children under the age of 5, who were hospitalized at a rate of 13.4 per 100,000.
More than 95% of the hospitalizations this flu season were the result of infection with an H3N2 strain of influenza, according to the CDC. Years that are dominated by H3N2 strains tend to involve more cases of severe illness and death, Dr. Tom Frieden, director of the CDC, has warned.
The CDC's surveillance continues to show that the other strains picked for the North American vaccines were on target, including the H1N1 virus A/California/7/2009 and the influenza B viruses Yamagata/16/88 and B/Victoria/02/87.
The FluView report also notes that all of the virus samples tested this fall have been susceptible to the main-line medicines Tamiflu (oseltamivir) and Relenza (zanamivir) as well as a new drug called Rapivab (peramivir).